Artificial Intelligence as a Disruptive Force in Pharmaceutical Innovation: Transforming Discovery, Development, and...

Area of Science:

• Pharmaceutical Sciences
• Computational Biology
• Drug Development

Background:

• Artificial Intelligence (AI) offers transformative potential across the pharmaceutical value chain, including drug discovery, manufacturing, and quality control.
• Despite AI's promise, significant hurdles impede its widespread adoption in the pharmaceutical sector.
• These challenges include data interoperability issues, model validation requirements, potential biases, and workforce skill gaps.

Purpose of the Study:

• To review current advancements in AI applications within pharmaceutical sciences.
• To identify critical factors for effective AI implementation.
• To provide strategic recommendations for navigating AI adoption in the pharmaceutical industry.

Main Methods:

• Consolidation of significant advancements in AI applications, including generative AI, laboratory automation, and digital twin concepts.
• Analysis of key requirements for successful AI integration, focusing on workflow, data quality, and human oversight.
• Development of strategic recommendations for assessing AI solutions and readiness.

Main Results:

• Effective AI implementation hinges on seamless workflow integration, high-quality data, and robust human-in-the-loop systems.
• Generative AI, laboratory automation, and digital twins represent key AI advancements in pharmaceuticals.
• Addressing data fragmentation, compliance, bias, and workforce skills is crucial for AI adoption.

Conclusions:

• Strategic recommendations focus on human resource development, governance frameworks, and technology maturity assessments.
• Future AI research and adoption will likely emphasize precision medicine and collaborative regulatory evaluation.
• Integration of AI with technologies like blockchain for provenance is still in early exploratory stages.